• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膳食天然产物作为新兴的脂蛋白(a)降低剂。

Dietary natural products as emerging lipoprotein(a)-lowering agents.

机构信息

Department of Medical Biotechnology, Nanotechnology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.

出版信息

J Cell Physiol. 2019 Aug;234(8):12581-12594. doi: 10.1002/jcp.28134. Epub 2019 Jan 13.

DOI:10.1002/jcp.28134
PMID:30637725
Abstract

Elevated plasma lipoprotein(a) (Lp(a)) levels are associated with an increased risk of cardiovascular disease (CVD). Hitherto, niacin has been the drug of choice to reduce elevated Lp(a) levels in hyperlipidemic patients but its efficacy in reducing CVD outcomes has been seriously questioned by recent clinical trials. Additional drugs may reduce to some extent plasma Lp(a) levels but the lack of a specific therapeutic indication for Lp(a)-lowering limits profoundly reduce their use. An attractive therapeutic option is natural products. In several preclinical and clinical studies as well as meta-analyses, natural products, including l-carnitine, coenzyme Q , and xuezhikang were shown to significantly decrease Lp(a) levels in patients with Lp(a) hyperlipoproteinemia. Other natural products, such as pectin, Ginkgo biloba, flaxseed, red wine, resveratrol and curcuminoids can also reduce elevated Lp(a) concentrations but to a lesser degree. In conclusion, aforementioned natural products may represent promising therapeutic agents for Lp(a) lowering.

摘要

血浆脂蛋白(a)(Lp(a))水平升高与心血管疾病(CVD)风险增加有关。迄今为止,烟酸一直是降低高脂血症患者升高的 Lp(a)水平的首选药物,但最近的临床试验严重质疑了其降低 CVD 结局的疗效。其他药物可以在一定程度上降低血浆 Lp(a)水平,但缺乏针对 Lp(a)降低的特定治疗指征,极大地限制了它们的使用。一种有吸引力的治疗选择是天然产物。在几项临床前和临床研究以及荟萃分析中,天然产物,包括左旋肉碱、辅酶 Q 和血脂康,被证明可显著降低 Lp(a)高脂蛋白血症患者的 Lp(a)水平。其他天然产物,如果胶、银杏叶、亚麻籽、红酒、白藜芦醇和姜黄素,也可以降低升高的 Lp(a)浓度,但程度较小。总之,上述天然产物可能是降低 Lp(a)的有前途的治疗药物。

相似文献

1
Dietary natural products as emerging lipoprotein(a)-lowering agents.膳食天然产物作为新兴的脂蛋白(a)降低剂。
J Cell Physiol. 2019 Aug;234(8):12581-12594. doi: 10.1002/jcp.28134. Epub 2019 Jan 13.
2
Latest developments in the treatment of lipoprotein (a).脂蛋白(a)治疗的最新进展。
Curr Opin Lipidol. 2014 Dec;25(6):452-60. doi: 10.1097/MOL.0000000000000126.
3
What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?降低脂蛋白(a)对心血管疾病和主动脉瓣狭窄有益的最终检验是什么?
Curr Opin Lipidol. 2014 Dec;25(6):423-30. doi: 10.1097/MOL.0000000000000131.
4
Flaxseed Supplementation Reduces Plasma Lipoprotein(a) Levels: A Meta-Analysis.亚麻籽补充剂可降低血浆脂蛋白(a)水平:一项荟萃分析。
Altern Ther Health Med. 2021 May;27(3):50-53.
5
Practical management of dyslipidemia with elevated lipoprotein(a).伴有脂蛋白(a)升高的血脂异常的实际管理
J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):803-7. doi: 10.1331/JAPhA.2008.07109.
6
Lp(a)-lowering drugs bolster cardiovascular pipeline.降低脂蛋白(a)的药物充实了心血管药物研发产品线。
Nat Rev Drug Discov. 2020 Mar;19(3):154-155. doi: 10.1038/d41573-020-00028-w.
7
A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury.一种新型降脂蛋白(a)药物D-47可减轻血管损伤后的新生内膜增厚。
J Med Invest. 2017;64(1.2):64-67. doi: 10.2152/jmi.64.64.
8
Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis.补充辅酶 Q10 可降低血浆脂蛋白(a)浓度,但不能降低其他血脂指标:系统评价和荟萃分析。
Pharmacol Res. 2016 Mar;105:198-209. doi: 10.1016/j.phrs.2016.01.030. Epub 2016 Feb 2.
9
When should we measure lipoprotein (a)?何时应检测脂蛋白(a)?
Eur Heart J. 2013 Nov;34(42):3268-76. doi: 10.1093/eurheartj/eht053. Epub 2013 Jun 4.
10
Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.降低脂蛋白(a)的新兴治疗选择:对心血管疾病预防的意义
Curr Atheroscler Rep. 2016 Dec;18(12):69. doi: 10.1007/s11883-016-0622-1.

引用本文的文献

1
Lipoprotein (a) in the Development and Progression of Diabetic Retinopathy: A Systematic Review and Meta-Analysis.脂蛋白(a)在糖尿病视网膜病变发生发展中的作用:一项系统评价和荟萃分析
Medicina (Kaunas). 2025 Jun 24;61(7):1137. doi: 10.3390/medicina61071137.
2
Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia.基于壳聚糖的纳米颗粒靶向递送系统:在血脂异常治疗方法中的应用
Int J Nanomedicine. 2025 May 24;20:6611-6636. doi: 10.2147/IJN.S517492. eCollection 2025.
3
Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?
正在研发的Lp(a)降低药物:应对心血管疾病风险负担的新时代?
Pharmaceuticals (Basel). 2025 May 19;18(5):753. doi: 10.3390/ph18050753.
4
Relationship between carotid atherosclerosis and lipoprotein (a) in patients with acute ischemic stroke.急性缺血性脑卒中患者颈动脉粥样硬化与脂蛋白(a)的关系
Front Neurol. 2024 Jun 26;15:1383771. doi: 10.3389/fneur.2024.1383771. eCollection 2024.
5
Role of natural products in cardiovascular disease.天然产物在心血管疾病中的作用。
Mol Cell Biochem. 2025 Feb;480(2):733-745. doi: 10.1007/s11010-024-05048-3. Epub 2024 Jun 16.
6
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.波兰心脏病学会(PCS)和波兰脂质协会(PoLA)专家关于脂蛋白(a)水平升高的诊断和管理的建议。
Arch Med Sci. 2024 Jan 31;20(1):8-27. doi: 10.5114/aoms/183522. eCollection 2024.
7
The ins and outs of lipoprotein(a) assay methods.脂蛋白(a)检测方法的来龙去脉。
Arch Med Sci Atheroscler Dis. 2023 Dec 30;8:e128-e139. doi: 10.5114/amsad/176653. eCollection 2023.
8
Ateroprotective effects of in. New Zealand rabbits: beyond the lipid-lowering effect.新西兰兔体内[具体物质未给出]的抗动脉粥样硬化作用:超越降脂作用。
Front Pharmacol. 2024 Jan 12;15:1244632. doi: 10.3389/fphar.2024.1244632. eCollection 2024.
9
Principal predictors of major adverse limb events in diabetic peripheral artery disease: A narrative review.糖尿病外周动脉疾病中主要肢体不良事件的主要预测因素:一项叙述性综述。
Atheroscler Plus. 2021 Nov 3;46:1-14. doi: 10.1016/j.athplu.2021.10.003. eCollection 2021 Dec.
10
Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy.针对脂蛋白(a)的靶向治疗:降脂治疗的即将到来的突破。
Pharmaceuticals (Basel). 2022 Dec 16;15(12):1573. doi: 10.3390/ph15121573.